Added to YB: 2026-05-25
Pitch date: 2026-05-21
EWTX [neutral]
Edgewise Therapeutics, Inc.
Author Info
Earnings Edge shares detailed earnings previews and recaps delivered lightning fast. Sign up for the newsletter.
Company Info
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Market Cap
$3.5B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-15.38
P/E
-19.68
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
Earnings Edge for Friday: Edgewise Therapeutics (EWTX)
EWTX (earnings): CIRRUS-HCM 12wk Part D efficacy data due this quarter for EDG-7500 in obstructive/nonobstructive HCM; no LVEF reductions or AFib vs competitors positions as best-in-class. Pivotal GRAND CANYON Becker MD results Q4 2026, first regulatory shot. Risks: binary trial events, -$2.13 2026 EPS, cash burn, no revenue, insider sales. Upside: dual franchise potential if both trials hit.
Read full article (2 min)